China Has Started Clinical Tests Of Inactivated Coronavirus Vaccines
The State Council of China has approved the start of clinical trials of the world's first two coronavirus vaccines. The tests have already begun, according to China's State News Agency Xinhua.
The vaccines are developed by the Wuhan Institute of biological products under the National pharmaceutical group of China (Sinopharm) and Sinovac Research and Development Co., Ltd, located in Beijing.
Both vaccines are inactivated, meaning they consist of laboratory-grown and then killed coronaviruses.
The developers note that the drugs are intended for large-scale vaccination, and they have the ability to produce large quantities.
In total, China is developing five types of coronavirus vaccines. In addition to inactivated vaccines, these are drugs with recombinant proteins (DNA sequences encoding enzymes and proteins for specific tasks), with adenovirus vectors (for delivering genetic material to cells), based on nucleic acids, and drugs that use weakened (attenuated) flu viruses. Since March 16, the Institute of military medicine Of the Academy of Military Sciences of the PRC has been testing a recombinant adenovirus vector vaccine.